By using several models of BCR::ABL+ CML and B-ALL, Neviani et al. showed that the knockdown of SET and treatment with FTY720 results in re-activation of PP2A which, in turn, dephosphorylates and deactivates BCR/ABL via SHP1. This evidence concerns the gene SET and chronic myelogenous leukemia, BCR-ABL1 positive.